Duaklir Genuair has been studied in 2 main
studies involving over 3,400 patients with COPD, in which it was compared with aclidinium alone, formoterol alone and placebo(a dummy treatment).
In addition, as long-acting muscarinic antagonists may have an effect on the heart and blood vessels,
the company that markets Brimica Genuair will provide the results of studies to further
evaluate the cardiovascular safety of the medicine.
In addition, as long-acting muscarinic antagonists may have an effect on the heart and blood vessels,
the company that markets Duaklir Genuair will provide the results of studies to further
evaluate the cardiovascular safety of the medicine.
Results showed that, after six months of treatment, the increase in FEV1(measured one hour after an inhalation) was 293 milliliters(ml)
more with Duaklir Genuair than with placebo
and 118 ml more with Duaklir Genuair than with aclidinium alone.